EICHORPublic-registry site landscape for NCT05762471, “Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus”, a Overweight or Obesity study sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05762471 (registry record) |
| Study title | Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus |
| Official title | A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus on Metformin |
| Sponsor | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics |
| Condition(s) | Overweight or Obesity; Type2 Diabetes Mellitus |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 4 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05762471.
Eichor generates a preliminary site-risk snapshot for NCT05762471 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Overweight or Obesity trials
← Eichor home · All tracked trials · Overweight or Obesity studies · Weekly briefs
